Beam Therapeutics Inc. (BEAM) stock intrinsic value fair value estimate & owner earnings analysis

Beam Therapeutics is a clinical-stage gene-editing company in Cambridge, Massachusetts. Its base-editing pipeline includes risto-cel (an ex vivo treatment for sickle cell disease), BEAM-302 (an in vivo treatment for alpha-1 antitrypsin deficiency, where the FDA has aligned on a possible accelerated approval path based on 12-month biomarker data), and earlier programs such as BEAM-301 and BEAM-304. It has no approved product and no product sales. All revenue to date has come from collaboration and licensing deals, mainly the release of upfront payments received in 2021-2023 (including the October 2023 agreement under which Eli Lilly took over rights under the Verve license). That deferred balance is now essentially used up: second-quarter 2026 revenue was only $0.5 million, against $139.7 million for 2025. What the business earns today: nothing. On our measure of owner earnings (operating cash flow, less working-capital timing effects, less stock compensation, less maintenance capital spending), the company lost $3.25 per share in 2025, $4.61 in 2024, $1.83 in 2023, $4.95 in 2022 and $3.59 in 2021. We treat the 2021-2025 median, about $3.6 per share or roughly $370 million a year, as the normal cost of running the current research programs. The 2023 figure looks better only because the Lilly transaction put non-cash revenue on the books. The 2025 gain of $255 million on selling the Verve stake is non-cash within operating cash flow and is not treated as earnings. Loss per share narrowed in 2025 mainly because there were more shares and lower stock compensation, not because cash use fell (operating cash outflow was $345 million in 2025 and $347 million in 2024). For the first half of 2026 it was $195 million, so we assume no improvement in cash use in year one. What the shares are backed by: cash and marketable securities of $1.15 billion at June 30, 2026, against a $100 million senior secured term loan from Sixth Street drawn in February 2026 (net about $1.05 billion, or roughly $10.20 per share on 103 million shares). A further $300 million under that facility is available only if risto-cel hits clinical, regulatory and commercial milestones, so we count it as neither cash nor value. The loan restricts asset sales and licensing of risto-cel and BEAM-302 and requires minimum liquidity if the company's market value falls below an agreed level. How we valued it: with no approved product, no signed collaboration revenue and no contracted future payments, we credit no value to the pipeline in any case. Clinical success, approvals, launches and new partnerships have not happened yet, so they are left out rather than discounted. What is left is the cash, less what the company spends before it stops. We use cash use of about $390 million a year, in line with the last two full years and the first half of 2026, discounted at 6%. Bear case, about $0.10 per share: spending continues at today's pace for three years, which is what the company did through 2024 and 2025 even after its October 2023 restructuring (about 20% of staff cut, some programs paused or dropped). The programs do not produce anything we can credit, and the cash is essentially gone, leaving little or nothing after the loan. Equity cannot fall below zero here because the company can stop spending, but leftover value is close to nil. Base case, about $3.20 per share: the company funds its three prioritised programs for two years, through the expansion of the BEAM-302 trial and the risto-cel regulatory process, and then curtails spending, as it did in October 2023, when it cut headcount and paused programs. About $1.05 billion less roughly $715 million of discounted spending leaves about $340 million; we round down slightly to allow for wind-down costs such as severance and leases. Bull case, about $5.00 per share: spending is curtailed after about 18 months, either because partners take on development cost or because management retrenches sooner, leaving about $510 million. No approval or product revenue is assumed even here. The upside if BEAM-302 or risto-cel reaches the market is not counted because it depends on trial outcomes and FDA decisions that have not yet occurred. What would make this wrong: if either lead program is approved and sells well, the shares would be worth far more than these figures. A partner paying real money for a program, as Lilly did in 2023, would also raise value. Conversely, the cases are also wrong if the company keeps spending well beyond its cash and must raise money by selling shares, which would dilute owners. The cash figure includes some marketable equity securities whose value moves with markets. Accounting judgements: we removed the timing effect of upfront collaboration payments and their later release to revenue, so the results show the underlying cash cost of running the business rather than swings from deal timing. Stock compensation ($94 million in 2025) is treated as a real cost. Capital spending was small ($15 million in 2025) and had minimal effect.